Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q6ZXV5

UPID:
TMTC3_HUMAN

ALTERNATIVE NAMES:
Protein SMILE; Transmembrane and TPR repeat-containing protein 3

ALTERNATIVE UPACC:
Q6ZXV5; Q5CZ86; Q5H9T6; Q68DQ6; Q68DX0; Q7Z332; Q8NC50

BACKGROUND:
The Transmembrane and TPR repeat-containing protein 3, or TMTC3, functions as an O-mannosyl-transferase, impacting various proteins including PDIA3. Its role extends to the positive regulation of proteasomal protein degradation and the control of ER stress response, highlighting its significance in cellular homeostasis.

THERAPEUTIC SIGNIFICANCE:
Given TMTC3's involvement in Lissencephaly 8, a disorder affecting cortical development, exploring its biological mechanisms opens doors to potential therapeutic strategies for this and possibly other neurodevelopmental diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.